Literature DB >> 28922730

Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer.

Weibo Xu1, Junkai Chang1, Xinyi Du1, Junqing Hou2.   

Abstract

Prostate cancer associated lncRNA transcript 1 (PCAT-1) has been identified as an oncogenic long non-coding RNA (lncRNA) in some solid tumors, including prostate cancer (PC). However, the molecular mechanism of PCAT-1 involved in PC is poorly defined. In this study, we found that PCAT-1 expression was up-regulated and miR-145-5p expression was down-regulated in PC tissues and cells. Function analysis indicated that PCAT-1 overexpression promoted proliferation, migration, invasion and inhibited apoptosis of PC cells. Rescue experiments demonstrated that miR-145-5p restoration attenuated the promotive effects of PCAT1 on PC progression, while Fascin-1 (FSCN1) upregulation relieved the anti-cancer role of miR-145-5p in PC. Mechanical analysis discovered that PCAT-1 could act as a miR-145-5p sponge to modulate FSCN1 expression. In conclusion, these findings suggested that PCAT-1 accelerated PC cell proliferation, migration, invasion and suppressed apoptosis by up-regulating FSCN1 mediated via miR-145-5p, hinting a potential therapeutic strategy for PC patients.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  FSCN1; Prostate cancer; lncRNA PCAT-1; miR-145-5p

Mesh:

Substances:

Year:  2017        PMID: 28922730     DOI: 10.1016/j.biopha.2017.09.019

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  37 in total

1.  Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma.

Authors:  Yao Zhang; Wei-Wei Ta; Peng-Fei Sun; Yi-Fan Meng; Cheng-Zong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

Review 2.  MiR-145: a potential biomarker of cancer migration and invasion.

Authors:  Wen-Xiu Xu; Zhen Liu; Fei Deng; Dan-Dan Wang; Xing-Wang Li; Tian Tian; Jian Zhang; Jin-Hai Tang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

3.  lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/β-catenin signaling pathway.

Authors:  Yuan Yuan; Qian Wang; Shu Li Ma; Long Qiang Xu; Meng Yang Liu; Bin Han; Ning Du; Xiao Lan Sun; Xiao Lin Yin; Fang Fang Cao
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

Review 4.  Long non-coding RNA in prostate cancer.

Authors:  Christine An; Ian Wang; Xin Li; Rong Xia; Fangming Deng
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

5.  Identification and functional analysis of LncRNA-XIST ceRNA network in prostate cancer.

Authors:  Jie Wang; Jie Huang; Yingxue Guo; Yuli Fu; Yifang Cao; Kang Zhou; Jianxiong Ma; Bodong Lv; Wenjie Huang
Journal:  BMC Cancer       Date:  2022-08-29       Impact factor: 4.638

6.  Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539.

Authors:  Rui Wang; Bin Zheng; Hongyan Liu; Xiuxian Wan
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

Review 7.  Long non-coding RNAs involved in different steps of cancer metastasis.

Authors:  P Suman; Y Chhichholiya; P Kaur; S Ghosh; A Munshi
Journal:  Clin Transl Oncol       Date:  2022-02-04       Impact factor: 3.405

Review 8.  Carcinogenesis in prostate cancer: The role of long non-coding RNAs.

Authors:  John Aird; Anne-Marie Baird; Marvin C J Lim; Ray McDermott; Stephen P Finn; Steven G Gray
Journal:  Noncoding RNA Res       Date:  2018-02-01

9.  LINC00992 contributes to the oncogenic phenotypes in prostate cancer via targeting miR-3935 and augmenting GOLM1 expression.

Authors:  Jianheng Chen; Xiaodong Liu; Kunbin Ke; Jianan Zou; Zhan Gao; Tomonori Habuchi; Xuezhen Yang
Journal:  BMC Cancer       Date:  2020-08-11       Impact factor: 4.430

10.  CircZNF609 promotes breast cancer cell growth, migration, and invasion by elevating p70S6K1 via sponging miR-145-5p.

Authors:  Shengting Wang; Xukai Xue; Rui Wang; Xiaoming Li; Qian Li; Yufang Wang; Peijun Xie; Yuhua Kang; Rui Meng; Xinghua Feng
Journal:  Cancer Manag Res       Date:  2018-09-25       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.